S. 4220 — Veterans Health Administration Novel Therapeutics Preparedness Act

This section states congressional findings concerning emerging therapeutic interventions, including psychedelic-assisted therapies under FDA evaluation, for treating post-traumatic stress disorder, depression, and other mental health conditions in veterans. The findings recognize that such therapies require intensive clinical engagement differing from traditional services; that the Department of Veterans Affairs is positioned to deliver integrated care; that absent centralized governance, the VA may face delays, safety risks, or inconsistent access post-regulatory approval; and that a dedicated Office of Novel Therapeutics is needed to ensure responsible evaluation, research, and implementation.

This section establishes within the Veterans Health Administration, under the Office of the Under Secretary for Health, the Office of Novel Therapeutics—headed by a Director with expertise in clinical research and implementation science who reports directly to the Under Secretary—to serve as the primary coordinating authority for emerging therapeutic interventions (i.e., pharmacological, biological, or other modalities under FDA evaluation or review), with duties that include (1) developing national policies, guidance, clinical standards, patient eligibility criteria, implementation-readiness plans (covering infrastructure, teams, protected clinical time, safety protocols, and integration with suicide prevention, PTSD, and substance use disorder programs), workforce assessments, training and credentialing standards, and continuity-of-care guidance; (2) distinguishing research protocols from clinical implementation; (3) coordinating with the Office of Research and Development on priorities, review pathways, and research time allocation; and (4) identifying at least one medical center per Veterans Integrated Service Network for infrastructure and workforce development, plus criteria for designating centers of excellence. This section further requires the Secretary, acting through the Office, to establish a Clinical Implementation Program for Emerging Therapeutics to evaluate such interventions' effectiveness, feasibility, safety, and scalability—prioritizing veterans' brain or mental health conditions such as post-traumatic stress disorder, treatment-resistant depression, substance use disorders, and suicidality—using hybrid effectiveness-implementation models that test care delivery, generate real-world evidence, and assess workforce, infrastructure, cost, and operational needs.